Semaglutide and phentermine are both used for medically supervised weight loss, but they work through entirely different mechanisms—one mimics a gut hormone, the other is a stimulant. TelosRX providers review both options asynchronously, subject to medical approval by a licensed provider.
If you've been researching weight-loss medications, you've likely hit the semaglutide vs phentermine question. Phentermine has been prescribed since the 1950s. Semaglutide is the active molecule in Ozempic and Wegovy. One is a Schedule IV controlled stimulant. The other is a hormone analog. That difference matters across every dimension of long-term weight management.
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist—a synthetic version of glucagon-like peptide-1, a hormone your intestines release after eating. It binds GLP-1 receptors in the pancreas, gut, and brain to slow gastric emptying, reduce appetite, and improve insulin sensitivity.
Compounded semaglutide is available through asynchronous telehealth pharmacies for patients who meet clinical criteria. In its compounded form, semaglutide is not FDA-approved. Learn more in our compounded semaglutide guide.
What Is Phentermine?
Phentermine is a Schedule IV sympathomimetic amine—a stimulant that raises norepinephrine and, to a lesser extent, dopamine in the brain. Higher norepinephrine suppresses appetite signals via the hypothalamus. The effect is fast, but it's a blunt instrument.
The FDA approved phentermine for short-term use, generally up to 12 weeks. Tolerance builds within weeks; appetite returns soon after stopping. It's one of the oldest weight-loss drugs still in active use.
Semaglutide vs Phentermine: Head-to-Head Comparison
These two medications differ across nearly every dimension relevant to a patient choosing long-term weight management support:
| Factor | Semaglutide | Phentermine |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Sympathomimetic amine (stimulant) |
| Mechanism | Slows gastric emptying; signals satiety to brain; improves insulin response | Raises norepinephrine to suppress appetite |
| Approved use duration | Long-term chronic weight management | Short-term only (≤12 weeks) |
| Average weight loss (trials) | ~14–15% body weight over 68 weeks | ~5–10% body weight over 12 weeks |
| Appetite mechanism | Reduces "food noise" via hypothalamic GLP-1 receptors | Sympathetic nervous system suppression |
| Blood sugar effect | Improves insulin sensitivity; used in T2D management | Can raise blood glucose via stimulant effect |
| Cardiovascular effects | Favorable CV outcomes in high-risk patients (SUSTAIN-6) | Contraindicated with heart disease, uncontrolled hypertension |
| DEA schedule | Not a controlled substance | Schedule IV controlled substance |
| Common side effects | Nausea, constipation, fatigue (dose-dependent, typically resolve) | Insomnia, elevated heart rate, anxiety, dry mouth |
| Weight rebound risk | Weight typically returns if stopped without lifestyle changes | High rebound risk once short course ends |
| Monthly cost (approx.) | Brand: $900–$1,400; compounded: substantially lower | Generic: $10–$30 |
How Semaglutide Regulates Appetite
GLP-1 receptors in the hypothalamus regulate satiety signaling. Semaglutide activates them, reducing what researchers describe as "food noise"—the persistent drive to eat even when not truly hungry. Most patients report thinking about food far less, rather than actively fighting cravings.
It also slows how fast food leaves your stomach, extending fullness after meals. The combined effect means most people eat fewer calories without the white-knuckling that characterizes stimulant-based appetite suppression. How GLP-1 works covers this mechanism in depth.
How Phentermine Regulates Appetite
Phentermine floods the brain with norepinephrine, a stress-response neurotransmitter whose side effect is appetite suppression. It works—within hours of the first dose. But the central nervous system adapts. Most patients plateau at 4–8 weeks, and hunger returns to baseline soon after stopping.
There's no downstream metabolic benefit. Phentermine doesn't improve insulin sensitivity, doesn't address cardiovascular risk, and doesn't change the hormonal environment driving the original weight gain.
Weight Loss Results: What the Evidence Shows
The STEP 1 trial—68 weeks, adults with obesity and no diabetes—found semaglutide 2.4 mg produced an average body weight reduction of 14.9% versus 2.4% with placebo. A 2024 systematic review published in Nutrients (PMC11979670) compared semaglutide against phentermine, orlistat, and liraglutide across multiple trials and found semaglutide produced significantly greater and more sustained weight reduction than the other agents.
Phentermine trials show 5–10% weight loss over 12 weeks. After stopping, most patients regain 50–75% of lost weight within one year—a pattern documented across multiple long-term follow-up studies, including a 2023 review in Obesity Reviews (PMID 34170647).
Appetite Mechanism: Why the Experience Feels Different
Patients who have tried both describe a distinct difference in how each drug changes their relationship with food. Phentermine produces a blunted, almost edgy quality to appetite suppression—hunger goes quiet, but energy, anxiety, and sometimes irritability go up. Most patients describe it as willpower on a leash: the drug holds your appetite back, but you still feel it straining.
Semaglutide is described differently. Most patients report simply not thinking about food as often. The intrusive thought cycle—what to eat, when to eat, wanting to eat even when not hungry—quiets. This is consistent with GLP-1 receptor action in the hypothalamus, which modulates the reward pathways associated with food anticipation, not just the hunger signal itself. It's a mechanistic difference that shows up in patient experience.
Side Effects and Who Should Avoid Each
Semaglutide side effects to know
- Nausea (most common, especially during dose escalation)
- Constipation or diarrhea
- Fatigue in early weeks
- Rare: pancreatitis risk; contraindicated with personal or family history of medullary thyroid cancer
Side effects are dose-dependent and usually resolve within a few weeks. Managing GLP-1 side effects walks through practical strategies for the transition period.
Phentermine side effects to know
- Elevated heart rate and blood pressure
- Insomnia (especially if taken late in the day)
- Anxiety and restlessness
- Dry mouth and constipation
- Dependency potential (Schedule IV controlled substance)
Phentermine is contraindicated with MAO inhibitors, uncontrolled hypertension, coronary artery disease, hyperthyroidism, glaucoma, and history of substance use disorders.
Muscle Mass: A Critical Difference
Any significant weight loss carries muscle loss risk. Semaglutide is no exception—patients in STEP trials lost lean mass alongside fat, especially without adequate protein and resistance training. Preserving lean mass on GLP-1 covers how to offset this.
Phentermine's mechanism doesn't protect muscle either. The caloric deficit it creates can accelerate lean mass loss when protein intake drops—a common pattern when appetite is heavily suppressed.
Cost and Access Through Telehealth
Brand-name Wegovy (semaglutide 2.4 mg) runs $900–$1,400/month without insurance. Compounded semaglutide through an asynchronous telehealth pharmacy like TelosRX is significantly more accessible—submit your intake form online, a licensed provider reviews asynchronously, and the prescription ships directly if approved. No live appointment required.
Generic phentermine costs $10–$30/month but requires a provider visit and carries the Schedule IV prescription constraints. Access varies by state.
Metabolic and Cardiovascular Differences
Semaglutide and phentermine diverge significantly when you look beyond weight on the scale. Semaglutide has demonstrated cardiovascular benefits in high-risk populations. The SUSTAIN-6 trial found that semaglutide 1 mg reduced the risk of major adverse cardiovascular events (MACE) versus placebo in patients with type 2 diabetes and established CVD or high cardiovascular risk.
Phentermine's cardiovascular profile is essentially the opposite. As a sympathomimetic, it raises heart rate and blood pressure—two factors that increase cardiovascular workload. It's contraindicated in patients with coronary artery disease, uncontrolled hypertension, and arrhythmia. For patients who carry both metabolic and cardiovascular risk, phentermine is often off the table before the conversation starts.
On blood sugar: semaglutide improves glucose metabolism by stimulating insulin secretion in a glucose-dependent way (meaning it triggers insulin only when blood sugar is elevated, reducing hypoglycemia risk). Phentermine can raise fasting glucose due to sympathetic activation. In a patient managing prediabetes or insulin resistance, this distinction often resolves the question.
Sustainability: What Happens After You Stop
Both medications carry weight regain risk after discontinuation. This is important to understand before starting either one.
For phentermine, regain is rapid because the drug provides no lasting change to the metabolic environment—only appetite suppression while you take it. Once tolerance develops or the prescription ends, hunger returns to its previous setpoint. Studies track 50–75% weight regain within a year of stopping.
Semaglutide produces more durable changes during use—the appetite reduction, slowed gastric emptying, and improved metabolic markers are meaningful—but most of them reverse when the medication is discontinued. A 2022 follow-up from the STEP 4 trial found that patients who stopped semaglutide regained approximately two-thirds of their lost weight within one year versus patients who continued. The implication: neither medication produces permanent, standalone results. They're tools that work while you use them, and lifestyle anchors (protein intake, resistance training, sustainable diet) determine how much ground is held after stopping.
Which Option Is Worth Considering?
This depends entirely on your individual health profile. Some practical distinctions:
- Insulin resistance or prediabetes: Semaglutide addresses the underlying metabolic pathway; phentermine doesn't, and can worsen glucose metabolism.
- Cardiovascular risk: Phentermine is typically contraindicated; semaglutide has demonstrated CV benefit in high-risk populations.
- Need for fast initial results: Phentermine acts within hours. Results come faster in weeks 1–4 but plateau and rebound.
- Long-term, sustained management: Semaglutide has substantially more clinical evidence for durable weight loss beyond 12 weeks.
- Budget: Phentermine is dramatically cheaper. Compounded semaglutide narrows this gap considerably.
All medications require evaluation and prescription from a licensed provider. Neither is appropriate for everyone. Approval is not guaranteed. Subject to medical approval by a licensed provider.
Frequently Asked Questions
Is semaglutide better than phentermine for weight loss?
Clinical data consistently shows semaglutide produces greater and more sustained weight loss than phentermine—roughly 15% body weight over 68 weeks versus 5–10% over 12 weeks. Whether it's better for you depends on your health profile, contraindications, and goals. A licensed provider should evaluate your full medical history before any decision. Individual results vary.
Can you take semaglutide and phentermine together?
Some providers prescribe the combination off-label, but clinical data on the combination's long-term safety profile is limited. Phentermine's cardiovascular effects require careful monitoring regardless. This decision requires close provider oversight and is not appropriate without a comprehensive clinical evaluation.
How long can you stay on phentermine?
Phentermine is FDA-approved for short-term use—typically 12 weeks or fewer. Some providers prescribe it longer off-label, but tolerance builds within 4–8 weeks for most patients, and cardiovascular monitoring becomes more important with prolonged use. The FDA label does not support long-term chronic use.
Is compounded semaglutide the same as Ozempic or Wegovy?
Compounded semaglutide contains the same active molecule as Ozempic and Wegovy but is not FDA-approved in its compounded form. It's prepared under federal compounding regulations by federally registered pharmacies. Ozempic (0.5–2 mg/week) is FDA-approved for type 2 diabetes; Wegovy (2.4 mg/week) is FDA-approved for chronic weight management. Dosing and formulations may differ in compounded versions.
Does phentermine affect blood sugar?
Yes. Phentermine's stimulant mechanism can elevate blood glucose by triggering stress-hormone release, including norepinephrine and epinephrine, which oppose insulin's effects. Unlike semaglutide, phentermine does not improve insulin sensitivity. It's generally avoided in patients with uncontrolled diabetes or significant metabolic disease.
Why do people regain weight after stopping phentermine?
Phentermine doesn't change the underlying hormonal or metabolic environment—it suppresses appetite through a stimulant mechanism while you take it. When you stop, hunger returns to baseline and the metabolic rate may remain suppressed from the caloric restriction. Semaglutide produces more durable changes by acting on the GLP-1 receptor system, though weight regain is also common after stopping GLP-1 therapy without lifestyle anchors in place.
Is semaglutide available without insurance?
Brand-name semaglutide without insurance runs $900–$1,400/month. Compounded semaglutide through LegitScript-certified telehealth pharmacies is substantially more affordable. TelosRX uses an asynchronous evaluation model—no live appointment required—and requires a valid provider-issued prescription for every patient. Approval is not guaranteed.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.